Autolus Therapeutics plc - American Depositary Share (AUTL) News

Autolus Therapeutics plc - American Depositary Share (AUTL)

Today's Latest Price: $13.44 USD

0.84 (-5.88%)

Updated Sep 21 6:55pm

Add AUTL to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

Filter AUTL News Items

AUTL News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest AUTL News From Around the Web

Below are the latest news stories about Autolus Therapeutics plc that investors may wish to consider to help them evaluate AUTL as an investment opportunity.

Autolus Therapeutics to host Investor Conference Call to discuss AUTO3 data presented at ESMO and to participate in Banking conferences through September

LONDON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO3 data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 and to participate in Banking conferences through September: * 9 September 2020 – The company will participate in an analyst moderated group meeting at the Wells Fargo Virtual Healthcare Conference at 9.20 am EDT, 2.20 pm BST and will also host virtual one-on-one meetings. A live audio webcast of the fireside chat will be available on the investor relations section of the Company’s website at Autolus. An archived replay will be ava...

Yahoo | September 8, 2020

Can You Imagine How Autolus Therapeutics' (NASDAQ:AUTL) Shareholders Feel About The 47% Share Price Increase?

If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right...

Yahoo | September 1, 2020

Autolus Therapeutics PLC (AUTL) CEO Christian Itin on Q2 2020 Results - Earnings Call Transcript

Autolus Therapeutics PLC (AUTL) Q2 2020 Earnings Conference Call August 06, 2020, 08:30 ET Company Participants Lucinda Crabtree - VP, IR & Corporate Communications Christian Itin - Chairman & CEO Andrew Oakley - CFO & SVP Conference Call Participants Mara Goldstein - Mizuho Securities Biren Amin - Jefferies Eric Joseph...

SA Transcripts on Seeking Alpha | August 9, 2020

Autolus Therapeutics plc 2020 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Autolus Therapeutics plc in conjunction with their 2020 Q2 earnings call....

SA Transcripts on Seeking Alpha | August 7, 2020

J.P. Morgan: These 2 Healthcare Stocks Are Must-Watch Names

Marching forward together, the previous decade saw equities and bonds rally right alongside each other. At the same time, there was a negative correlation of daily returns, limiting portfolio volatility. This was a good thing for multi-asset portfolios like pension funds which benefited from the high-low frequency correlation, with declining yields also giving a bump to specific equity market sectors.Today, things have changed, with bond yields landing at almost zero. According to J.P. Morgan strategist Marko Kolanovic, this implies that the trend might be fading away, which poses a major threat to multi-asset portfolios.“Should yields (or inflation expectations) start rising, these portfolios could experience a triple-whammy: bond values would go lower, valuations of the above-describe...

Yahoo | August 5, 2020

Autolus announces changes to its Board and Management Team

Dr. Jay T. Backstrom appointed to board of directorsLONDON, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Dr. Jay T Backstrom to its Board of Directors, effective August 1, 2020. Dr. Backstrom currently serves as EVP, Head of Research & Development at Acceleron Pharma Inc (Acceleron) and prior to that served as Chief Medical Officer and Head of Regulatory Affairs at Celgene Corporation. Additionally, the Company announced that Dr. Nushmia Khokhar has been promoted to Senior Vice President, Clinical Development, and will take over the medical leadership role at Autolus.  Dr. Khokhar is a board-certified oncologist with extensiv...

Yahoo | August 4, 2020

Autolus: Progress Developing Next Generation Car-T Therapies Ought To Lift Share Price

Investment Thesis Autolus share price performance since IPO. Source: TradingView. Autolus (AUTL), a developer of next-generation programmed T cell therapies, has taken some time to come to the boil but its treatments are now showing significant signs of promise. The company has endured a number of frustrating setbacks (which I...

Edmund Ingham on Seeking Alpha | July 8, 2020

Hedge Funds Are Buying Autolus Therapeutics plc (AUTL)

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

Yahoo | July 2, 2020

Moving Average Crossover Alert: Autolus Therapeutics

Autolus Therapeutics plc (AUTL) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Yahoo | June 24, 2020

Autolus Therapeutics presents new preclinical data during the Virtual 2020 AACR Annual Meeting

Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced preclinical data related to AUTO5 in T cell lymphoma and AUTO6NG in small cell lung cancer, as well as an oral presentation related to AUTO7 in prostate cancer at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on June 22 - 24, 2020. “Behind our lead programs AUTO1 in ALL and AUTO3 in DLBCL, we have a number of exciting preclinical product candidates progressing towards the clinic,” said Dr Christian Itin, chairman and chief executive officer of Autolus.

Yahoo | June 22, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4348 seconds.